chills with semaglutide What Is the Dark Side of Semaglutide? A new study analyzed over

As we stand on the cusp of breakthroughs in obesity treatment, GLP-1 agonists appear poised to play a significant role in shaping the future landscape of weight management strategies

Cytotherapy 18, 10871099

[DOI] [PMC free article] [PubMed] [Google Scholar] 51.Sun Y., Bai T., Zhou L., Zhu R., Wang W., Liang R., Li J., Zhang C., Gou J

Stopping the medication abruptly can lead to weight regain, so I always recommend a personalized plan for tapering off when the time is right

Patients on either medication typically follow the same escalation timeline: weeks 1-4 at 0.25 mg, weeks 5-8 at 0.5 mg, weeks 9-12 at 1.0 mg, weeks 13-16 at 1.7 mg, and weeks 17+ at the 2.4 mg maintenance dose